ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,212.20
0.10%
S&P ASX All Technology
3,444.90
0.35%
Brent Oil
71.345
0.56%
US Dollar vs AUD
1.44865
-0.15%
Bitcoin
66,062.60
1.35%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Europe
  5. EU
  6. Ipsen SA (IPN)

  7. Ipsen SA (IPN) News

IPN

Ipsen (IPN)

Ipsen SA
Date:
Sort by:
 Showing the most relevant articles for your search:EU:IPN
DateTimeSourceHeadlineSymbolCompany
23/09/202421:13GlobeNewswire Inc.Ipsen’s Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare liver diseaseEU:IPNIpsen SA
20/09/202422:57GlobeNewswire Inc.Ipsen’s Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decadeEU:IPNIpsen SA
16/09/202422:45GlobeNewswire Inc.Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumorsEU:IPNIpsen SA
15/09/202422:45GlobeNewswire Inc.Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysisEU:IPNIpsen SA
26/07/202420:46GlobeNewswire Inc.Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseasesEU:IPNIpsen SA
25/07/202415:00GlobeNewswire Inc.Ipsen delivers strong results in the first half of 2024, progresses on launches and upgrades its full-year guidanceEU:IPNIpsen SA
11/07/202415:00GlobeNewswire Inc.Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potentialEU:IPNIpsen SA
09/07/202402:00GlobeNewswire Inc.Bilan semestriel du contrat de liquidité d'IPSEN - 2024 06 30EU:IPNIpsen SA
09/07/202402:00GlobeNewswire Inc.Half-year statement of IPSEN liquidity agreement - 2024 06 30EU:IPNIpsen SA
03/07/202402:00GlobeNewswire Inc.IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 26 - 2024EU:IPNIpsen SA
03/07/202402:00GlobeNewswire Inc.IPSEN - Buy-back programme - Art 5 of MAR - Week 26 - 2024EU:IPNIpsen SA
02/07/202415:00GlobeNewswire Inc.Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trialEU:IPNIpsen SA
02/07/202415:00GlobeNewswire Inc.Ipsen étend sa collaboration et son accord de licence pour le développement de Cabometyx® dans le traitement des tumeurs neuroendocrines avancées sur la base des résultats positifs de l’essai de Phase III CABINETEU:IPNIpsen SA
02/07/202415:00GlobeNewswire Inc.Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trialEU:IPNIpsen SA
26/06/202402:00GlobeNewswire Inc.IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2024EU:IPNIpsen SA
26/06/202402:00GlobeNewswire Inc.IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 25 - 2024EU:IPNIpsen SA
19/06/202402:00GlobeNewswire Inc.IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2024EU:IPNIpsen SA
19/06/202402:00GlobeNewswire Inc.IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 24 - 2024EU:IPNIpsen SA
12/06/202402:00GlobeNewswire Inc.IPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2024EU:IPNIpsen SA
12/06/202402:00GlobeNewswire Inc.IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 23 - 2024EU:IPNIpsen SA
11/06/202406:54GlobeNewswire Inc.Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitisEU:IPNIpsen SA
11/06/202406:54GlobeNewswire Inc.Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitisEU:IPNIpsen SA
11/06/202406:54GlobeNewswire Inc.Le médicament Iqirvo® d’Ipsen obtient l’approbation de la FDA via une procédure accélérée comme traitement PPAR premier de sa classe thérapeutique pour la cholangite biliaire primitiveEU:IPNIpsen SA
07/06/202415:00GlobeNewswire Inc.Ipsen et Marengo Therapeutics annoncent la conclusion d’un second partenariat stratégique afin de faire progresser les actifs « T-Cell Engager » de précision de la plateforme TriSTAR de MarengoEU:IPNIpsen SA
07/06/202415:00GlobeNewswire Inc.Ipsen and Marengo Therapeutics announce second strategic partnership to advance precision T cell engagers from Marengo’s Tri-STAR platformEU:IPNIpsen SA
07/06/202415:00GlobeNewswire Inc.Ipsen and Marengo Therapeutics announce second strategic partnership to advance precision T cell engagers from Marengo’s Tri-STAR platformEU:IPNIpsen SA
07/06/202402:00GlobeNewswire Inc.Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital socialEU:IPNIpsen SA
07/06/202402:00GlobeNewswire Inc.Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capitalEU:IPNIpsen SA
06/06/202422:30GlobeNewswire Inc.Ipsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer   EU:IPNIpsen SA
06/06/202422:30GlobeNewswire Inc.Ipsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer   EU:IPNIpsen SA
 Showing the most relevant articles for your search:EU:IPN

Your Recent History

COIN
MORPHGBP
COIN
PDTUSD
PARADISE TOKEN
NYSE
AMH-D
American Homes 4 Rent
LSE
46FP
Rep. Kaz 1.55%a
TSXV
DVT
Divestco Inc.
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved